• Stephen L Hauser and CreeBruce A CBACUCSF Weill Institute for Neurosciences and Department of Neurology, University of California, San Francisco..
• UCSF Weill Institute for Neurosciences and Department of Neurology, University of California, San Francisco. Electronic address: stephen.hauser@ucsf.edu.
• Am. J. Med. 2020 Dec 1; 133 (12): 1380-1390.e2.

AbstractMultiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system, and the leading cause of nontraumatic neurological disability in young adults. Effective management requires a multifaceted approach to control acute attacks, manage progressive worsening, and remediate bothersome or disabling symptoms associated with this illness. Remarkable advances in treatment of all forms of MS, and especially for relapsing disease, have favorably changed the long-term outlook for many patients. There also has been a conceptual shift in understanding the immune pathology of MS, away from a purely T-cell-mediated model to recognition that B cells have a key role in pathogenesis. The emergence of higher-efficacy drugs requiring less frequent administration have made these preferred options in terms of tolerability and adherence. Many experts now recommend use of these as first-line treatment for many patients with early disease, before permanent disability is evident.Copyright © 2020 Elsevier Inc. All rights reserved.

12 keywords...

hide…